JP2005502675A - 喘息治療用の製薬組成物 - Google Patents

喘息治療用の製薬組成物 Download PDF

Info

Publication number
JP2005502675A
JP2005502675A JP2003524562A JP2003524562A JP2005502675A JP 2005502675 A JP2005502675 A JP 2005502675A JP 2003524562 A JP2003524562 A JP 2003524562A JP 2003524562 A JP2003524562 A JP 2003524562A JP 2005502675 A JP2005502675 A JP 2005502675A
Authority
JP
Japan
Prior art keywords
mometasone furoate
formoterol fumarate
metered dose
dose inhaler
aerosol suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003524562A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005502675A5 (es
Inventor
ジョエル エー． セクエイラ，
ステファン エー． シャープ，
ジョン エル． ハート，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23224164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2005502675(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2005502675A publication Critical patent/JP2005502675A/ja
Publication of JP2005502675A5 publication Critical patent/JP2005502675A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
JP2003524562A 2001-08-28 2002-08-27 喘息治療用の製薬組成物 Pending JP2005502675A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31538601P 2001-08-28 2001-08-28
PCT/US2002/027336 WO2003020253A2 (en) 2001-08-28 2002-08-27 Pharmaceutical compositions for the treatment of asthma

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2009126933A Division JP2009185075A (ja) 2001-08-28 2009-05-26 喘息治療用の製薬組成物
JP2010036706A Division JP5170789B2 (ja) 2001-08-28 2010-02-22 喘息治療用の製薬組成物

Publications (2)

Publication Number Publication Date
JP2005502675A true JP2005502675A (ja) 2005-01-27
JP2005502675A5 JP2005502675A5 (es) 2006-01-05

Family

ID=23224164

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2003524562A Pending JP2005502675A (ja) 2001-08-28 2002-08-27 喘息治療用の製薬組成物
JP2009126933A Pending JP2009185075A (ja) 2001-08-28 2009-05-26 喘息治療用の製薬組成物
JP2010036706A Expired - Fee Related JP5170789B2 (ja) 2001-08-28 2010-02-22 喘息治療用の製薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009126933A Pending JP2009185075A (ja) 2001-08-28 2009-05-26 喘息治療用の製薬組成物
JP2010036706A Expired - Fee Related JP5170789B2 (ja) 2001-08-28 2010-02-22 喘息治療用の製薬組成物

Country Status (27)

Country Link
US (3) US20030114428A1 (es)
EP (3) EP2092935B1 (es)
JP (3) JP2005502675A (es)
KR (1) KR100970531B1 (es)
CN (2) CN1649568B (es)
AR (1) AR036358A1 (es)
AT (2) ATE503461T1 (es)
AU (1) AU2002313828B2 (es)
BR (1) BR0212089A (es)
CA (1) CA2457926A1 (es)
CO (1) CO5560551A2 (es)
CY (2) CY1109212T1 (es)
DE (2) DE60232251D1 (es)
DK (2) DK1420759T3 (es)
ES (3) ES2325316T3 (es)
HK (3) HK1060972A1 (es)
HU (1) HUP0401514A3 (es)
MX (1) MXPA04001875A (es)
NO (1) NO20041277L (es)
NZ (1) NZ530987A (es)
PE (1) PE20030390A1 (es)
PL (1) PL209640B1 (es)
PT (2) PT1420759E (es)
SI (2) SI2092935T1 (es)
TW (1) TWI324934B (es)
WO (1) WO2003020253A2 (es)
ZA (1) ZA200401419B (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005536538A (ja) * 2002-08-23 2005-12-02 シェーリング　コーポレイション 薬学的組成物
JP2010518076A (ja) * 2007-02-09 2010-05-27 シェーリング コーポレイション 安定な医薬エアロゾル製剤
JP2019503997A (ja) * 2015-12-04 2019-02-14 メキシケム フロー エセ・ア・デ・セ・ヴェ 薬学的組成物

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
DE50211045D1 (de) * 2001-03-30 2007-11-22 Jagotec Ag Medizinische aerosolformulierungen
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
EP1785156B1 (en) * 2002-08-23 2012-06-27 Schering Corporation Metered dose inhaler containing an aerosol suspension formulation
AU2003265639A1 (en) * 2002-08-27 2004-03-19 Schering Corporation Process for producing metered dose inhaler formulations
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
WO2005041931A2 (en) * 2003-10-20 2005-05-12 Schering Corporation Pharmaceutical aerosol compositions
EP1925293A3 (en) * 2003-10-20 2010-01-13 Schering Corporation Pharmaceutical aerosol compositions
ES2340777T3 (es) * 2004-01-21 2010-06-09 Schering Corporation Metodo de tratamiento de la rinosinusitis aguda.
US20110053999A1 (en) * 2004-03-03 2011-03-03 Daley Thomas E 4-methylpyrazole formulations for inhibiting ethanol intolerance
ES2317306T3 (es) * 2004-10-12 2009-04-16 Generics (Uk) Limited Procedimiento para la preparacion de formulaciones en aerosol en suspension, en el que las particulas se forman por precipitacion dentro de un frasco de aerosol.
EP2484382A1 (en) 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
WO2007095039A2 (en) * 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products
GB0714239D0 (en) * 2007-07-20 2007-08-29 Glaxo Group Ltd Method
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
EP2244692A2 (en) * 2008-01-10 2010-11-03 Schering Corporation Inhalation drug products, systems and uses
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
US10011906B2 (en) 2009-03-31 2018-07-03 Beohringer Ingelheim International Gmbh Method for coating a surface of a component
EP3508239B1 (de) 2009-05-18 2020-12-23 Boehringer Ingelheim International GmbH Adapter, inhalationseinrichtung und zerstäuber
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US9463161B2 (en) * 2009-05-29 2016-10-11 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
WO2011027247A1 (en) 2009-09-03 2011-03-10 Sulur Subramaniam Vanangamudi An antifungal cream comprising terbinafine hydrochloride
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
JP5715640B2 (ja) 2009-11-25 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
EP2504051B1 (en) 2009-11-25 2019-09-04 Boehringer Ingelheim International GmbH Nebulizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
AU2010328375B2 (en) 2009-12-07 2015-08-27 Raptor Therapeutics Inc. 4-methylpyrazole formulations
WO2011101830A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and clobetasone, and a process to make it
WO2011101828A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sidium fusidate and incorporating a biopolymer and betamethasone, and a process to make it
EP2585151B1 (en) 2010-06-24 2018-04-04 Boehringer Ingelheim International GmbH Nebulizer
WO2012017368A1 (en) 2010-08-02 2012-02-09 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, beclomethasone dipropionate and a process to make it
WO2012049543A1 (en) 2010-10-15 2012-04-19 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a corticosteroid, and a process to make it
EP2694220B1 (de) 2011-04-01 2020-05-06 Boehringer Ingelheim International GmbH Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
SI2765994T1 (sl) * 2011-10-11 2019-02-28 Chiesi Farmaceutici S.P.A. Kristalni mikrodelci beta-agonista, obloženi z maščobno kislino
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
EP2835146B1 (en) 2013-08-09 2020-09-30 Boehringer Ingelheim International GmbH Nebulizer
WO2015018904A1 (en) 2013-08-09 2015-02-12 Boehringer Ingelheim International Gmbh Nebulizer
HUE055604T2 (hu) 2014-05-07 2021-12-28 Boehringer Ingelheim Int Porlasztó
JP6580070B2 (ja) 2014-05-07 2019-09-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 容器、ネブライザ、及び使用
BR112016023932B1 (pt) 2014-05-07 2022-11-29 Boehringer Ingelheim International Gmbh Nebulizador
AU2015284195B2 (en) 2014-06-30 2019-01-24 Proveris Scientific Corporation Sampling apparatus for determining the amount and uniformity of a delivered dose of drug related methods
EP3383366B1 (en) 2015-12-04 2020-03-25 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
CA3016890A1 (en) 2016-03-09 2017-09-14 Proveris Scientific Corporation Methods for measuring dose content uniformity performance of inhaler and nasal devices
CN106619658B (zh) * 2016-12-28 2022-02-08 四川普锐特药业有限公司 一种医用气溶胶制剂及定量吸入气雾剂
US20210338626A1 (en) 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06511235A (ja) * 1991-06-10 1994-12-15 シェリング・コーポレーション クロロフルオロカーボン不含エアゾール製剤
JPH10510829A (ja) * 1994-12-22 1998-10-20 アストラ・アクチエボラーグ エアゾール製剤
JP2000503673A (ja) * 1996-08-29 2000-03-28 シェーリング コーポレイション クロロフルオロカーボンを含まないモメタゾンフロエートエーロゾルの処方物
WO2000051591A1 (en) * 1999-03-03 2000-09-08 Novartis Ag Combinations of formoterol and mometasone furoate for asthma
WO2000053187A1 (en) * 1999-03-09 2000-09-14 Astrazeneca Ab New combination of formoterol and mometasone in a pharmaceutical composition for treating respiratory disorders, such as asthma, rhinitis and copd
JP2000513340A (ja) * 1996-06-11 2000-10-10 ミネソタ マイニング アンド マニュファクチャリング カンパニー 医用ホルモテロールエアゾール製剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
US6250300B1 (en) * 1992-12-11 2001-06-26 Ab Astra System for dispensing pharmaceutically active compounds
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
TW533865U (en) * 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
JP3840515B2 (ja) * 1998-11-26 2006-11-01 ブリタニア・ファーマスーティカルズ・リミテッド 界面活性リン脂質を含む抗喘息の組合せ
AR022695A1 (es) * 1999-01-28 2002-09-04 Schering Corp PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
JP2003535042A (ja) * 2000-01-20 2003-11-25 バジリア ファルマスーチカ アーゲー 鼻腔に投与可能な環式ペプチド組成物
GB0009612D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
CA2417973A1 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06511235A (ja) * 1991-06-10 1994-12-15 シェリング・コーポレーション クロロフルオロカーボン不含エアゾール製剤
JPH10510829A (ja) * 1994-12-22 1998-10-20 アストラ・アクチエボラーグ エアゾール製剤
JP2000513340A (ja) * 1996-06-11 2000-10-10 ミネソタ マイニング アンド マニュファクチャリング カンパニー 医用ホルモテロールエアゾール製剤
JP2000503673A (ja) * 1996-08-29 2000-03-28 シェーリング コーポレイション クロロフルオロカーボンを含まないモメタゾンフロエートエーロゾルの処方物
WO2000051591A1 (en) * 1999-03-03 2000-09-08 Novartis Ag Combinations of formoterol and mometasone furoate for asthma
WO2000053187A1 (en) * 1999-03-09 2000-09-14 Astrazeneca Ab New combination of formoterol and mometasone in a pharmaceutical composition for treating respiratory disorders, such as asthma, rhinitis and copd

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005536538A (ja) * 2002-08-23 2005-12-02 シェーリング　コーポレイション 薬学的組成物
JP2006312649A (ja) * 2002-08-23 2006-11-16 Schering Plough Corp 薬学的組成物
JP2010518076A (ja) * 2007-02-09 2010-05-27 シェーリング コーポレイション 安定な医薬エアロゾル製剤
JP2019503997A (ja) * 2015-12-04 2019-02-14 メキシケム フロー エセ・ア・デ・セ・ヴェ 薬学的組成物
JP2020073514A (ja) * 2015-12-04 2020-05-14 メキシケム フロー エセ・ア・デ・セ・ヴェ 薬学的組成物
JP6993335B2 (ja) 2015-12-04 2022-01-13 メキシケム フロー エセ・ア・デ・セ・ヴェ 薬学的組成物
JP6993398B2 (ja) 2015-12-04 2022-01-13 メキシケム フロー エセ・ア・デ・セ・ヴェ 薬学的組成物

Also Published As

Publication number Publication date
JP2010138184A (ja) 2010-06-24
US20050147565A1 (en) 2005-07-07
WO2003020253A2 (en) 2003-03-13
BR0212089A (pt) 2004-08-03
EP2092935A1 (en) 2009-08-26
CN101856362A (zh) 2010-10-13
MXPA04001875A (es) 2004-06-15
EP2319494B1 (en) 2012-06-13
PL209640B1 (pl) 2011-09-30
EP1420759B1 (en) 2009-05-06
CN1649568B (zh) 2010-10-27
CN1649568A (zh) 2005-08-03
ATE430555T1 (de) 2009-05-15
ES2389480T3 (es) 2012-10-26
HK1151987A1 (en) 2012-02-17
KR20040031002A (ko) 2004-04-09
CA2457926A1 (en) 2003-03-13
ATE503461T1 (de) 2011-04-15
PE20030390A1 (es) 2003-04-24
HK1060972A1 (en) 2004-09-03
ES2325316T3 (es) 2009-09-01
DK1420759T3 (da) 2009-08-03
ES2361805T3 (es) 2011-06-22
EP2092935B1 (en) 2011-03-30
DK2092935T3 (da) 2011-07-18
AR036358A1 (es) 2004-09-01
AU2002313828B2 (en) 2005-09-08
ZA200401419B (en) 2005-01-26
KR100970531B1 (ko) 2010-07-16
CY1109212T1 (el) 2014-07-02
HUP0401514A3 (en) 2012-08-28
PT1420759E (pt) 2009-06-30
TWI324934B (en) 2010-05-21
EP2319494A1 (en) 2011-05-11
DE60239648D1 (de) 2011-05-12
US20030114428A1 (en) 2003-06-19
DE60232251D1 (de) 2009-06-18
JP5170789B2 (ja) 2013-03-27
HUP0401514A2 (hu) 2004-12-28
SI2092935T1 (sl) 2011-07-29
JP2009185075A (ja) 2009-08-20
US20100143269A1 (en) 2010-06-10
HK1128428A1 (en) 2009-10-30
SI1420759T1 (sl) 2009-10-31
NO20041277L (no) 2004-03-26
PT2092935E (pt) 2011-05-31
WO2003020253A3 (en) 2003-05-22
EP1420759A2 (en) 2004-05-26
NZ530987A (en) 2006-08-31
PL368897A1 (en) 2005-04-04
CY1111726T1 (el) 2015-10-07
CO5560551A2 (es) 2005-09-30

Similar Documents

Publication Publication Date Title
JP5170789B2 (ja) 喘息治療用の製薬組成物
AU2002313828A1 (en) Pharmaceutical compositions for the treatment of asthma
JP3776124B2 (ja) 少なくとも一種の糖を含んでなる医薬用エアゾール
US20100095963A1 (en) Pharmaceutical compositions
US6068832A (en) Chlorofluorocarbon-free mometasone furoate aerosol formulations
JP3264496B2 (ja) クロロフルオロカーボンを含まないモメタゾンフロエートエーロゾルの処方物
WO2013026269A1 (zh) 制备用于治疗呼吸道疾病的定量喷雾吸入剂的工艺方法
EP1785156B1 (en) Metered dose inhaler containing an aerosol suspension formulation
US20110182830A1 (en) Inhalation drug products, systems and uses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100120

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100420